Summit Therapeutics (SMMT) losing Wall Street's confidence after FDA rejection
FROM THE WIRE · FINANCE.YAHOO.COM
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Investors Are Fleeing. Summit Therapeutics extended its losing streak to a 5th consecutive day on Tuesday to hit a new 52-week low, as investors resumed selling positions after the Food and Drug Administration (FDA)…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe FDA rejection of the lung cancer treatment application weighs on the stock, which hit a record low.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The stock closed down 9.73% at $10.67 after an intraday low of $10.53.
- 02The FDA rejected the BLA for lack of substantial evidence of effectiveness.
- 03The rejection cites the absence of a statistically significant improvement in overall survival.
- 04The stock extended its losing streak to five consecutive days.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets